Publications

Title

Author

Year

Impact of Reversion of Mycobacterium tuberculosis Immunoreactivity Tests on the Estimated Annual Risk of Tuberculosis Infection.

SCHWALB, A; Emery, JC; Dale, KD; HORTON, KC; Ugarte-Gil, CA; HOUBEN, RM G J;

2023

American journal of epidemiology, (2023).192 12 10.1093/aje/kwad028.

CAD4TB software updates: different triaging thresholds require caution by users and regulation by authorities.

Fehr, J; Gunda, R; Siedner, MJ; Hanekom, W; Ndung U, T; GRANT, A; Lippert, C; Wong, EB;

2023

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, (2023).27 2 10.5588/ijtld.22.0437.

Genome-wide host-pathogen analyses reveal genetic interaction points in tuberculosis disease.

PHELAN, J; Gomez-Gonzalez, PJ; Andreu, N; Omae, Y; Toyo-Oka, L; Yanai, H; Miyahara, R; Nedsuwan, S; De Sessions, PF; CAMPINO, S; Sallah, N; Parkhill, J; Smittipat, N; Palittapongarnpim, P; Mushiroda, T; Kubo, M; Tokunaga, K; Mahasirimongkol, S; HIBBERD, ML; CLARK, TG;

2023

Nature communications, (2023).14 1 10.1038/s41467-023-36282-w.

Treatment for radiographically active, sputum culture-negative pulmonary tuberculosis: a systematic review and meta-analysis.

Gray, AT; Macpherson, L; Carlin, F; Sossen, B; RICHARDS, A; Kik, S; Houben, R; MacPherson, P; Quartagno, M; Rogozińska, E; Esmail, H;

2023

medRxiv (2023). 10.1101/2023.01.27.23285085.

Contribution of remote M.tuberculosis infection to tuberculosis disease: A 30-year population study.

GLYNN, JR; KHAN, P; Mzembe, T; Sichali, L; FINE, PE M; CRAMPIN, AC; HOUBEN, RM G J;

2023

PloS one, (2023).18 1 10.1371/journal.pone.0278136.

The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.

Portnoy, A; CLARK, RA; Quaife, M; WEERASURIYA, CK; Mukandavire, C; Bakker, R; Deol, AK; Malhotra, S; Gebreselassie, N; Zignol, M; Sim, SY; Hutubessy, RC W; Baena, IG; Nishikiori, N; JIT, M; WHITE, RG; Menzies, NA;

2023

PLOS Medicine, (2023).20 1 10.1371/journal.pmed.1004155.

Second-line drug resistance markers as proxy indicators of time to sputum culture conversion among second-line drug resistant tuberculosis patients tested in Uganda: A cross-sectional study.

Mujuni, D; Ssengooba, W; Ibanda, I; Kabugo, JS; Kasemire, DL; Nampewo, E; Nsawotebba, A; PHELAN, JE; Tugumisirize, D; Orena, B; Byabajungu, H; Ntenkaire, N; Nadunga, D; Tumwine, J; Musisi, K; Joloba, M; Kim, S; Kokas, I; Mukani, WO; Kungu, J; Afayoa, M;

2023

F1000Research, (2023).12, 10.12688/f1000research.129524.1.

Large-scale genomic analysis of Mycobacterium tuberculosis reveals extent of target and compensatory mutations linked to multi-drug resistant tuberculosis.

Napier, G; CAMPINO, S; PHELAN, JE; CLARK, TG;

2023

Scientific reports, (2023).13 1 10.1038/s41598-023-27516-4.

Dataset codebook for a 30-year population-based study examining the contribution of remote M.tuberculosis infection to tuberculosis.

GLYNN, JR;

2023

, London School of Hygiene & Tropical Medicine (London, United Kingdom) (2023). 10.17037/DATA.00002829.

Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis.

Hamada, Y; Gupta, RK; Quartagno, M; Izzard, A; Acuna-Villaorduna, C; Altet, N; Diel, R; Dominguez, J; FLOYD, S; Gupta, A; Huerga, H; Jones-López, EC; Kinikar, A; Lange, C; Van Leth, F; Liu, Q; Lu, W; Lu, P; Rueda, IL; Martinez, L; Mbandi, SK; Muñoz, L; Padilla, ES; Paradkar, M; Scriba, T; ... Rangaka, MX.

2023

EClinicalMedicine, (2023).56, 10.1016/j.eclinm.2022.101815.